References

Important Safety Information for CRESTOR Tablets

• CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers
• Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with statins, including CRESTOR. These risks can occur at any dose level but are increased at the highest dose (40 mg)
• CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, lopinavir/ritonavir, or atazanavir/ritonavir
• Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever
• It is recommended that liver enzyme tests be performed before the initiation of CRESTOR and if signs or symptoms of liver injury occur. All patients treated with CRESTOR should be advised to promptly report any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including CRESTOR. If serious liver injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment with CRESTOR, promptly interrupt therapy. If an alternate etiology is not found, do not restart CRESTOR
• CRESTOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a history of chronic liver disease
• CRESTOR significantly increased INR in patients receiving coumarin anticoagulants. In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs
• Dipstick-positive proteinuria and microscopic hematuria were observed among patients treated with CRESTOR. These findings were more frequent in patients taking CRESTOR 40 mg, though it was generally transient and was not associated with worsening renal function. Although the clinical significance of this finding is unknown, dose reduction should be considered for patients on CRESTOR therapy with unexplained persistent proteinuria and/or hematuria during routine urinalysis testing
• Increases in HbA1c and fasting serum glucose levels have been reported with statins, including CRESTOR
• In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%)^#‡‡
• Rare postmarketing reports of cognitive impairment (eg, memory loss, forgetfulness, amnesia, memory impairment, confusion) have been associated with statin use, including CRESTOR. These reports are generally nonserious and reversible upon statin discontinuation
• The dose range for CRESTOR is 5 mg to 40 mg orally once daily. The usual starting dose is 10 mg to 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose. After initiation or upon titration of CRESTOR, lipid levels should be analyzed within 2 to 4 weeks and the dosage adjusted accordingly. CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg

Indications

• CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels
• CRESTOR is indicated to reduce the risk of myocardial infarction, stroke, and arterial revascularization procedures in patients without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men ≥50 and women ≥60), high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and the presence of at least one additional CVD risk factor, such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease

Read full Prescribing Information (PDF - 152k)

Please see the full Prescribing Information available at CrestorTouchPoints.com

CRESTOR is licensed from SHIONOGI & CO, LTD, Osaka, Japan.

CRESTOR is a registered trademark of the AstraZeneca group of companies.

©2012 AstraZeneca. All rights reserved. 1569505 3/12

• Privacy Statement | 
• Legal Information | 
• Contact Us | 
• Site Map

  This product information is intended for US health care professionals only.

• Ballantyne CM, Bertolami M, Hernandez Garcia HR, et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006;151(5):975.e1-975.e9.
• Bays HE, Deedwania PC, Jones PH, et al. Comparative effects of statins on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in patients ≥65 years of age. Poster presented at Annual Scientific Meeting of the American Geriatrics Society. Las Vegas, NV, May 17-21, 2004.
• Berne C, Siewert-Delle A; URANUS Study Investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;4:7.
• Betteridge DJ, Gibson JM; ANDROMEDA Study Investigators. Effects of rosuvastatin on lipids, lipoproteins, and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med. 2007;24(5):541-549.
• Crouse JR III, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344-1353.
• Data on File 266987, AstraZeneca Pharmaceuticals LP.
• Data on File, 266992, AstraZeneca Pharmaceuticals LP.
• Data on File, 267725, AstraZeneca Pharmaceuticals LP.
• Data on File, 268255, AstraZeneca Pharmaceuticals LP.
• Data on File, 295753, AstraZeneca Pharmaceuticals LP.
• Data on File, 1403806, AstraZeneca Pharmaceuticals LP.
• Drugs@FDA Website. Label and Approval History for CRESTOR^® (rosuvastatin calcium). Available at: www.accessdata.fda.gov. Accessed on August 30, 2010.
• Faergeman O, Hill L, Windler E, et al; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-228.
• Faergeman O, Sosef F, Duffield E; on behalf of the ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force titrated in high-risk patients: results from the ECLIPSE Study. Poster presented at: 14th International Symposium on Atherosclerosis; June 18-22, 2006; Rome, Italy.
• Ferdinand KC, Clark LT, Watson KE, et al; ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. AM J Cardiol. 2006;97(2):229-235.
• Fingertip Formulary^®. Percentage of covered lives without prior authorization. Glen Rock, NJ: Fingertip Formulary LLC. www.fingertipformulary.com. Accessed October 12, 2011.
• Grundy SM, Cleeman JI, Merz NB, et al, for the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
• Jones PH, Davidson MH, Stein EA, et al; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;93(2):152-160.
• Jukema JW, Liem AH, Dunselman PH, et al. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin. 2005;21(11):1865-1874.
• Libby P. The pathogenesis, prevention, and treatment of atherosclerosis. In: Fauci AS, Braunwald E, Kasper DL, et al, eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY: The McGraw-Hill Companies, Inc.; 2008;1501-1509
• Libby P. The vascular biology of atherosclerosis. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, PA: Elsevier Saunders; 2005:921-937.
• Lloret R, Ycas J, Stein M, Haffner S; STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. 2006;98(6):768-773.
• McKenney JM, Jones PH, Adamczyk MA, et al; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-698.
• Naghavi M, Falk E, Hecht HS, et al, for SHAPE Task Force. From vulnerable plaque to vunerable patient-part III: executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) task force. Am J Cardiol. 2006;98(suppl):2H-15H.
• National Institutes of Health, National Heart, Lung, and Blood Institute. Your Guide to Lowering Your Cholesterol with TLC. Bethesda, MD: National Institutes of Health; December 2005. NIH Publication No. 06-5235.
• Prescribing Information for CRESTOR. AstraZeneca Pharmaceuticals LP, Wilmington, DE.
• Prescribing Information for Lescol. Novartis, East Hanover, NJ.
• Prescribing Information for Lipitor. Pfizer US Pharmaceuticals, New York, NY.
• Prescribing Information for Livalo. Eli Lilly Company, Indianapolis, IN.
• Prescribing Information for Mevacor. Merck & Co., Inc., Whitehouse Station, NJ.
• Prescribing Information for Pravachol. Bristol-Myers Squibb Company, Princeton, NJ.
• Prescribing Information for Vytorin. Merck/Schering-Plough Pharmaceuticals, North Wales, PA.
• Prescribing Information for Zocor. Merck & Co., Inc., Whitehouse Station, NJ.
• Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I) study. Am Heart J. 2004;147(4):705-712.
• Wolffenbuttel BH, Franken AA, Vincent HH; Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes - CORALL Study. J Intern Med. 2005;257(6):531-539.